Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market Analysis 2034 - Competitive Landscape, Clinical Trials, Market Share, Therapies, Prevalence, Companies by DelveInsight

Potential Pulmonary Hypertension Associated with Interstitial Lung Disease Therapies are TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others
DelveInsight's analysis reveals a rising burden of Interstitial Lung Disease (ILD) across major markets, with over 1 million diagnosed prevalent cases reported in the 7MM in 2024 and numbers projected to grow by 2034. In the US, more than 80,000 cases of pulmonary hypertension associated with ILD (PH-ILD) were recorded in 2024, alongside increasing cases of key subtypes such as idiopathic pulmonary fibrosis (IPF). The PH-ILD market-valued at around USD 3 billion in 2024-is expected to expand through 2034, driven by recent advancements including TYVASO and the 2025 approval of YUTREPIA. A strong pipeline featuring candidates like Treprostinil liposomal (L606), TPIP, Mosliciguat, and H1614 is advancing through clinical development, with major companies such as Liquidia Corporation, Pharmosa BioPharm, and United Therapeutics focusing on innovation to address unmet patient needs and improve long-term outcomes.

DelveInsight's "Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Pulmonary Hypertension Associated with Interstitial Lung Disease, historical and forecasted epidemiology as well as the Pulmonary Hypertension Associated with Interstitial Lung Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The PH-ILD market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted PH-ILD market size from 2020 to 2034, segmented by seven major markets. The Report also covers current PH-ILD treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the PH-ILD market.

To Know in detail about the PH-ILD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some of the key facts of the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Report:

* The PH-ILD market size in the 7MM was approximately USD 1,400 million in 2023. PH-ILD Market is expected to increase by 2034 at a significant CAGR.
* According to DelveInsight's projections, the diagnosed prevalent cases of PH-ILD in the 7MM were estimated to be around 166,375 in the year 2021.
* Based on our analysis, the diagnosed prevalent population of PH-ILD in the United States was the highest among the 7MM, with an estimated 87,295 cases in 2021.
* In 2021, Germany had the largest diagnosed prevalent population of PH-ILD among the five major European countries, with 13,868 cases, followed by the United Kingdom, France, and Italy. Spain had the lowest number of PH-ILD cases in Europe, with 8,954 cases in the same year.
* In 2021, the highest number of type-specific cases of PH-ILD in the United States was attributed to IIPs, totaling 50,941 cases.
* During the forecast period, upcoming products like L606, TPIP, and others are expected to be launched.
* Key PH-ILD Companies: Insmed Incorporated, Bellerophon Therapeutics, United Therapeutics, Bayer, Biogen, and others
* Key PH-ILD Therapies: TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others
* The PH-ILD market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Hypertension Associated with Interstitial Lung Disease pipeline products will significantly revolutionize the Pulmonary Hypertension Associated with Interstitial Lung Disease market dynamics.
* In March 2025, Liquidia Corporation (NASDAQ: LQDA) announced that the FDA has accepted its New Drug Application (NDA) resubmission for YUTREPIA Trademark (treprostinil) inhalation powder, intended to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

PH-ILD Overview

Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) is a severe and progressive condition where high blood pressure develops in the lung's arterial system as a complication of underlying interstitial lung diseases (ILDs). This dual burden of vascular damage and lung fibrosis significantly worsens exercise capacity, oxygen requirements, and overall survival compared to ILD alone. Treatment strategies focus on managing the ILD itself, supportive measures like oxygen therapy and rehabilitation, and targeted vascular therapies. Early diagnosis is difficult but crucial for improving outcomes and slowing disease progression.

Get a Free sample for the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Forecast, Size & Share Analysis Report [https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology

In 2024, in the US, the diagnosed prevalence of PH-ILD showed a slightly higher burden in males, with approximately 42,000 cases compared to 39,000 in females, and this gender gap is expected to widen by 2034, suggesting potential differences in disease susceptibility or progression. In the same year, an estimated 69,000 people in the EU4 and the UK were diagnosed with PH-ILD, reflecting a substantial and growing disease burden across the region. In France, connective tissue disease-related PH-ILD recorded the highest diagnosed prevalence, at nearly 4,000 cases in 2024, whereas hypersensitivity pneumonitis was associated with the lowest burden, with just over 500 cases. Japan reported more than 28,000 diagnosed prevalent cases of PH-ILD in 2024, and the number is expected to rise further by 2034, indicating increasing public health concern. Idiopathic pulmonary fibrosis accounted for the largest share of PH-ILD cases in Japan at 21% in 2024, while hypersensitivity pneumonitis represented only 1%, highlighting notable variation in subtype distribution and the need for subtype-specific diagnostic and treatment approaches.

Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology Segmentation:

The Pulmonary Hypertension Associated with Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

* Total Prevalence of PH-ILD
* Prevalent Cases of PH-ILD by severity
* Gender-specific Prevalence of PH-ILD
* Diagnosed Cases of Episodic and Chronic PH-ILD

Download the report to understand which factors are driving PH-ILD epidemiology trends @ [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Pulmonary Hypertension Associated with Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Hypertension Associated with Interstitial Lung Disease market or expected to get launched during the study period. The analysis covers Pulmonary Hypertension Associated with Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pulmonary Hypertension Associated with Interstitial Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pulmonary Hypertension Associated with Interstitial Lung Disease Therapies and Key Companies

* TPIP: Insmed Incorporated
* INOpulse: Bellerophon Therapeutics
* Inhaled Treprostinil: United Therapeutics
* Riociguat (Adempas, BAY63-2521): Bayer
* Bardoxolone methyl: Biogen

Discover more about therapies set to grab major Pulmonary Hypertension Associated with Interstitial Lung Disease market share @ [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

PH-ILD Market Drivers

* The worldwide population and improvement in diagnosis are resulting in a rise in PH prevalence associated with several types of ILDs. This rise in cases is supposed to strengthen the market in the future.
* Treatment demand for PH-ILD is increasing, with a lack of therapies to manage the disease burden. Hence, the market is vast and up for any key player developing a novel therapy.

PH-ILD Market Barriers

* Expected approval of potential therapies can increase market size.
* Lucrative opportunities for market growth in the studied countries, owing to the presence of a large pool of patients suffering from PH-ILD

Scope of the PH-ILD Market Report

* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Pulmonary Hypertension Associated with Interstitial Lung Disease Companies: Insmed Incorporated (NASDAQ: INSM), Bellerophon Therapeutics (NASDAQ: BLPH), United Therapeutics (NASDAQ: UTHR), Bayer (ETR: BAYN), Biogen (NASDAQ: BIIB), and others.
* Key Pulmonary Hypertension Associated with Interstitial Lung Disease Therapies: TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others
* Pulmonary Hypertension Associated with Interstitial Lung Disease Therapeutic Assessment: Pulmonary Hypertension Associated with Interstitial Lung Disease current marketed and Pulmonary Hypertension Associated with Interstitial Lung Disease emerging therapies
* Pulmonary Hypertension Associated with Interstitial Lung Disease Market Dynamics: Pulmonary Hypertension Associated with Interstitial Lung Disease market drivers and Pulmonary Hypertension Associated with Interstitial Lung Disease market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Pulmonary Hypertension Associated with Interstitial Lung Disease Unmet Needs, KOL's views, Analyst's views, Pulmonary Hypertension Associated with Interstitial Lung Disease Market Access and Reimbursement

To know more about Pulmonary Hypertension Associated with Interstitial Lung Disease companies working in the treatment market, visit @ [https://www.delveinsight.com/sample-request/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Table of Contents

1. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Report Introduction

2. Executive Summary for Pulmonary Hypertension Associated with Interstitial Lung Disease

3. SWOT analysis of Pulmonary Hypertension Associated with Interstitial Lung Disease

4. Pulmonary Hypertension Associated with Interstitial Lung Disease Patient Share (%) Overview at a Glance

5. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Overview at a Glance

6. Pulmonary Hypertension Associated with Interstitial Lung Disease Disease Background and Overview

7. Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Pulmonary Hypertension Associated with Interstitial Lung Disease

9. Pulmonary Hypertension Associated with Interstitial Lung Disease Current Treatment and Medical Practices

10. Pulmonary Hypertension Associated with Interstitial Lung Disease Unmet Needs

11. Pulmonary Hypertension Associated with Interstitial Lung Disease Emerging Therapies

12. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Outlook

13. Country-Wise Pulmonary Hypertension Associated with Interstitial Lung Disease Market Analysis (2020-2034)

14. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Access and Reimbursement of Therapies

15. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Drivers

16. Pulmonary Hypertension Associated with Interstitial Lung Disease Market Barriers

17. Pulmonary Hypertension Associated with Interstitial Lung Disease Appendix

18. Pulmonary Hypertension Associated with Interstitial Lung Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pulmonary-hypertension-associated-with-interstitial-lung-disease-phild-market-analysis-2034-competitive-landscape-clinical-trials-market-share-therapies-prevalence-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.